Highlights in Asthma Therapy From CHEST 2022

Navitha Ramesh, MD


November 09, 2022

Dr Navitha Ramesh, of the University of Pittsburgh Medical Center in Harrisburg, Pennsylvania, reports the latest research on biologic therapy in patients with asthma as presented at CHEST 2022.

Dr Ramesh highlights a clinical study evaluating whether stopping, restarting, or continuing biologic therapy affects clinical outcomes and healthcare resource utilization (HCRU) for patients with severe asthma. The study found that patients who stopped or switched biologic therapy experienced worse outcomes and more extensive HCRU than those who continued using one biologic therapy.

Next, Dr Ramesh discusses the ZEPHYR 2 study, which looked at the real-world effectiveness of benralizumab for patients with severe eosinophilic asthma over 24 months. The study found that benralizumab is an effective long-term treatment for reducing asthma exacerbations in this patient population.

Finally, Dr Ramesh examines two studies analyzing data from the phase 3 NAVIGATOR trial. The first study looked at patients treated with tezepelumab and one, two, or three additional controller medications at baseline. The results indicated that irrespective of the number of additional controller medications the patient received, tezepelumab was effective. The second study, using pooled data from NAVIGATOR and the phase 2b PATHWAY study, showed that tezepelumab improved exacerbations and lung function, compared with placebo, in patients with uncontrolled asthma, despite receiving medium or high-dose inhaled corticosteroids or other controller medications.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.